Clinical Trials

Text Size A A

E-Mail to a Friend



secret  Click to Play Audio


Send To Friend

SCCA Clinical Studies: Phase 1 Program

SGN-75 + Everolimus for Metastatic Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Status Conditions Phase Study ID
Recruiting Renal Cell Carcinoma Phase I NCT01677390
Summary

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.


Investigator
John A. Thompson, MD
Location    
SCCA Phase 1 Program Office 206-288-7551 Refer Patient
Eligibility Criteria (must meet the following to participate in this study)
  • Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression
  • Previously treated with 1 or 2 tyrosine kinase inhibitors (TKIs)
  • Measurable disease
  • Eastern Cooperative Oncology Group performance status 0 or 1
  • Adequate lung and renal function
Exclusions (conditions that would prevent participation in this study)
  • Prior treatment with anti-CD70-directed therapy
  • Prior treatment with an mTOR inhibitor
    •
    Last Updated
    October 02, 2012
    See this trial at ClinicalTrials.gov
    Access protocol and consent forms at Fred Hutchinson Cancer Research Center
    Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

    Please remember:
    • Talk to your health care providers first before making decisions about your health care.
    • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.